The multifaceted biology of PCSK9
NG Seidah, A Prat - Endocrine reviews, 2022 - academic.oup.com
This article reviews the discovery of PCSK9, its structure–function characteristics, and its
presently known and proposed novel biological functions. The major critical function of …
presently known and proposed novel biological functions. The major critical function of …
[HTML][HTML] Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
E Raschi, M Casula, AFG Cicero, A Corsini… - Pharmacology & …, 2023 - Elsevier
The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models
RG Lee, AM Mazzola, MC Braun, C Platt, SB Vafai… - Circulation, 2023 - Am Heart Assoc
Background: VERVE-101 is an investigational in vivo CRISPR base-editing medicine
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …
[HTML][HTML] Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation …
Background In patients with ST-segment elevation myocardial infarction (STEMI), early
initiation of high-intensity statin therapy, regardless of low-density lipoprotein (LDL) …
initiation of high-intensity statin therapy, regardless of low-density lipoprotein (LDL) …
VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
MM Vroom, H Lu, M Lewis, BA Thibodeaux… - Journal of Lipid …, 2024 - ASBMB
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of disease
burden in the world and is highly correlated with chronic elevations of low-density …
burden in the world and is highly correlated with chronic elevations of low-density …
Inclisiran for the treatment of hyperlipidemia and for atherosclerotic cardiovascular disease risk reduction: a narrative review
Purpose Inclisiran is a novel nonstatin therapy providing significant reduction in low-density
lipoprotein cholesterol (LDL-C) as well as improvements in other lipid biomarkers. This …
lipoprotein cholesterol (LDL-C) as well as improvements in other lipid biomarkers. This …
[HTML][HTML] Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry
AMH Galema-Boers, JWCM Mulder, K Steward… - Atherosclerosis, 2023 - Elsevier
Background and aims Proprotein convertase subtilisin/kexin 9 monoclonal antibodies
(PCSK9 mAbs) reduce low-density lipoprotein (LDL-c) with a favourable safety profile …
(PCSK9 mAbs) reduce low-density lipoprotein (LDL-c) with a favourable safety profile …
Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice
CK Bradley, AA Kolkailah, NP Shah, CB Page… - Journal of Clinical …, 2023 - Elsevier
Nearly two-thirds of individuals with atherosclerotic cardiovascular disease (ASCVD) do not
reach target low-density lipoprotein cholesterol despite statin therapy. Three novel lipid …
reach target low-density lipoprotein cholesterol despite statin therapy. Three novel lipid …
Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tank
KA Krychtiuk, TLG Andersson, U Bodesheim… - American Heart …, 2024 - Elsevier
The global pharmaceutical industry portfolio is skewed towards cancer and rare diseases
due to more predictable development pathways and financial incentives. In contrast, drug …
due to more predictable development pathways and financial incentives. In contrast, drug …
Lipid‐lowering treatment among older patients with atherosclerotic cardiovascular disease
Background The contemporary uptake of lipid‐lowering therapies (LLT), including more
intensive treatment with high‐intensity statins and non‐statin LLT, among US older adults …
intensive treatment with high‐intensity statins and non‐statin LLT, among US older adults …